Similar but different BRAF and KRAS mutation roles in oncogenesis generate potential implications for the treatment of invasive mucinous ovarian carcinoma and highlight a challenge in its response to conventional chemotherapy compared to high-grade serous carcinomas. This evidence concerns the gene KRAS and serous adenocarcinoma.